From: Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
Healthy | Asthma | |
---|---|---|
Number | 21 | 25 |
Sex (m/f) | 10/11 | 13/12* |
Age | 38.5+/− 13.1 | 43.8 +/−12.0* |
Age of asthma diagnosis | N/A | 16.1 +/−16.0 |
Body Mass Index | 25.7 +/− 3.5 | 27.3 +/− 3.3* |
Atopy (Y/N) | 1/20 | 21/4a |
ACQ score | N/A | 1.85 +/− 0.79 |
FEV1 % predicted | 103.7+/−17.2 | 72.4 +/− 15.5*** |
FEV1/FVC | 78.8 +/−5.4 | 65.8 +/− 10.4*** |
Reversibility (%) | 3.2 +/− 2.6 | 18.9 +/− 17.4** |
SABA (y/n) | 0/21 | 24/1a |
LABA (y/n) | 0/21 | 21/4a |
ICS (y/n) | 0/21 | 25/0** |
Beclomethasone dose (μg/day) | 0 | 1125+/− 558 |
BAL cell yields (×106/ml BAL) | 0.099 +/− 0.038 | 0.107 +/−0.072* |